Pharma News, 2026

The FDA has approved Desmoda (desmopressin acetate) oral solution by Eton Pharmaceuticals for managing central diabetes insipidus in adults and children.

Asahi Kasei is acquiring Aicuris Anti-infective Cures for $920.7m to expand its specialty pharma platform into severe infectious diseases and boost R&D.

The FDA released draft guidance for an ultra-rare disease therapy pathway, the Plausible Mechanism Framework, and fast-tracked lung cancer drug Hernexeos.

Quotient Sciences and Ipsen extend their commercial partnership to produce Sohonos for FOP, enhancing HPAPI capabilities at the Boothwyn, PA facility.

Panacea Biotec's single-dose dengue vaccine candidate, DengiAll, advances to Phase III trials, offering hope for India's first domestic dengue prevention.

IQVIA Holdings agrees to acquire selected drug discovery assets from Charles River Laboratories to expand its end-to-end R&D and early-stage capabilities.

EPFL researchers have developed new preclinical models and successfully tested PXS-5505, a promising new drug targeting invasive lobular breast carcinoma.

Soligenix receives a positive EMA COMP opinion for SGX945 orphan drug designation to treat Behçet's Disease, advancing its novel dusquetide therapy.

Explore how agentic AI can automate and improve clinical trial setups while emphasizing the critical need for human oversight and strong governance protocols.

HotSpot Therapeutics will present preclinical data from its IRF5 small molecule inhibitor program at the 15th European Lupus Meeting in Lisbon, Portugal.

The FDA has accepted Beren Therapeutics' NDA for adrabetadex, a potential disease-modifying treatment for infantile-onset Niemann-Pick disease type C.

Gibson Oncology enters Phase 2 clinical trials with LMP744 to treat first-time recurrent glioblastoma, targeting topoisomerase 1 and cMYC oncogene inhibition.